Petrelintide

Zealand Pharma engineered petrelintide, development code ZP8396, to mimic the pancreatic satiety hormone amylin with sufficient stability and duration for once-weekly injection. Development involves Roche and includes plans to study a combination with a separate incretin medicine. It remains an experimental product without an approved use.

Amylin-receptor activation reproduces fullness signaling. Proposed effects include lower appetite, slower stomach emptying and reduced glucagon secretion, together helping reduce food intake. Amylin signaling differs from the GLP-1 and GIP incretin pathways, creating a rationale for combination research. Mechanistic complementarity alone does not prove better patient outcomes.

Petrelintide is not approved by FDA or another regulator in the described development record. Developers plan Phase 3 registration studies, and further Phase 2 findings in people with type 2 diabetes are expected.

The available evidence centers on one placebo-controlled Phase 2 trial, ZUPREME-1, enrolling people with obesity without diabetes. Mean weight loss was approximately 9–10% at 28 weeks and continued to about 11% at 42 weeks.

Mild nausea was the principal reported adverse effect; overall gastrointestinal tolerability resembled placebo. These positive Phase 2 findings do not replace completed Phase 3 testing or establish longer-term efficacy and safety.